Omada for Diabetes Program Achieves Key Clinical Outcomes
Early Participants Significantly Reduce Average Blood Sugar Levels
San Francisco, CA (May 1, 2020) - New data from an initial cohort of participants in the Omada for Diabetes Program demonstrates that participants achieved clinically-meaningful reductions in hemoglobin A1C levels as measured by blood test. Participants who began the program with a baseline A1C level at or above 7 percent reduced their A1C by 1.1 points, on average. Those with a baseline A1C below 7 percent maintained their A1C at goal, as measured by treatment guidelines published by the American Diabetes Association. Overall, 85 percent of participants in the group achieved their A1C goals while in the Omada Program. Blood value reductions were recorded among participants with both a baseline and follow-up A1C value from either participant-reported lab data, or an at-home A1C test kit.
“Omada’s approach to digital care means delivering meaningful results in real-world settings,” said company Co-Founder and CEO Sean Duffy. “So we design our program to amplify the expertise and empathy of our coaches, and enable them to build real relationships with our participants over the course of the Omada Program. These results demonstrate the impact of our approach - and the outcomes and value our Diabetes Program can deliver.”
In addition to being paired with a Certified Diabetes Care and Education Specialist who provides proactive care, individuals in the Omada for Diabetes program have access to personalized curriculum, a connected glucometer, and a peer group dealing with similar challenges. Participants reported a 92 percent satisfaction rate with the Omada for Diabetes program, with three of every four stating that access to the program increased appreciation of their health plan or employer. Omada will publish a white paper in the coming weeks with additional details on the early cohort results. Reporting on blood value reductions in hemoglobin A1C is an example of Omada’s commitment to delivering outcomes that meet clinical standards, and customers can trust.
Peer-reviewed literature indicates that for every one point reduction in A1C:
- Risk of heart attack declines by 14 percent;
- Risk of stroke declines by 12 percent; and
- Risk of death from diabetes decreases by 21 percent
In October, Omada announced a partnership with Abbott to integrate the revolutionary FreeStyle Libre System, a continuous glucose monitoring (CGM) technology, into the Omada for Diabetes Program. The integrated solution, available to health plans and employers, will provide real-time glucose data to Omada coaches in order to guide participants with personalized recommendations from their coaches and enable them to better manage their diabetes.
About Omada Health
Omada Health is a digital care company that inspires and engages people to achieve their health goals, one step at a time. The company’s programs are personalized to meet each participant’s unique needs as they evolve, ranging from diabetes prevention, type 2 diabetes management, and behavioral health. Omada combines professional health coaching, connected health devices, real-time data and personalized feedback to deliver clinically meaningful results. The company is the largest CDC-recognized provider of the National Diabetes Prevention Program. Omada Health was named a 2016 Technology Pioneer by the World Economic Forum, and one of Fast Company’s Most Innovative Companies in 2017. To learn more, visit www.omadahealth.com.